Related Experiment Videos
Levosimendan compared with dobutamine in low output patients
1Division of Cardiology, University Central Hospital, Helsinki, Finland. markku.nieminen@hus.fi
Minerva Anestesiologica
|May 27, 2003
Summary
Levosimendan significantly improves cardiac function and reduces mortality in heart failure patients compared to dobutamine. This drug is better tolerated, with fewer adverse events like arrhythmias and ischemia.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) management often involves inotropic agents.
- Dobutamine is a commonly used inotrope, but its efficacy and safety profile are subjects of ongoing research.
- Levosimendan offers a potential alternative with a different mechanism of action.
Purpose of the Study:
- To compare the hemodynamic efficacy and safety of levosimendan versus dobutamine in patients with acute heart failure.
- To evaluate the short- and long-term effects of these treatments on cardiac function, mortality, and adverse events.
Main Methods:
- Two studies were reviewed: a dose-finding trial and a randomized, double-blind comparison.
- Participants included patients with NYHA class II-III or severe low-output heart failure.
- Treatments involved continuous infusions of levosimendan or dobutamine.
Main Results:
- Levosimendan demonstrated significantly greater improvements in cardiac function compared to dobutamine.
- A significant reduction in 31-day and 180-day mortality was observed with levosimendan.
- Levosimendan increased days alive and out of hospital and was better tolerated, with fewer arrhythmias and myocardial ischemia.
Conclusions:
- Levosimendan provides superior hemodynamic benefits and improved clinical outcomes in acute heart failure compared to dobutamine.
- Levosimendan is associated with a better safety profile, including reduced risk of arrhythmias and ischemia.
- The positive effects of levosimendan were consistent regardless of heart failure etiology or concurrent beta-blocker use.